Abstract
Purpose: To utilize a novel circulating tumor cell (CTC) technology to quantify ERCC1 expression on CTCs and determine whether ERCC1 expression levels predict efficacy of platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer (NSCLC). Experimental design: ERCC1 expression was measured in 17 metastatic NSCLC patients who received platinum-based therapy and had ≥2 intact CTCs with acceptable ERCC1 expression assay results. ERCC1 levels were determined from average expression on individual CTCs in each sample. Progression-free survival (PFS) was calculated from the date of therapy initiation. Results: PFS decreased with increasing ERCC1 expression (p<0.04, F-test, linear regression). Lack of ERCC1 expression was associated with longer PFS (266 days versus 172 days, log-rank, p<0.02) in a Kaplan-Meier analysis using ERCC expression level of 1 as a cutoff (range 0-30). The difference in survival was statistically significant with a hazard ratio of 4.20 (95% CI 1.25-14.1, p<0.02, log-rank). PFS was also observed to decrease with increased cytokeratin (CK) expression (p<0.01 long-rank (Cox regression) and F-test (linear regression)). The hazard ratio is 4.38 (95% CI 1.76-10.9) for each log-change in CK value until progression was noted on imaging. Conclusion: Low expression of ERCC1 on CTCs correlates with PFS in patients with metastatic NSCLC receiving platinum-based therapy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 421-426 |
| Number of pages | 6 |
| Journal | Lung Cancer |
| Volume | 77 |
| Issue number | 2 |
| DOIs | |
| State | Published - Aug 2012 |
| Externally published | Yes |
Fingerprint
Keywords
- Circulating tumor cells
- ERCC1
- Non-small-cell lung cancer
- Platinum-based chemotherapy
- Prognostic diagnostic
ASJC Scopus subject areas
- Oncology
- Pulmonary and Respiratory Medicine
- Cancer Research
Cite this
ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy. / Das, Millie; Riess, Jonathan; Frankel, Paul; Schwartz, Erich; Bennis, Robyn; Hsieh, H. Ben; Liu, Xiaohe; Ly, Janey C.; Zhou, Lisa; Nieva, Jorge J.; Wakelee, Heather A.; Bruce, Richard H.
In: Lung Cancer, Vol. 77, No. 2, 08.2012, p. 421-426.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy
AU - Das, Millie
AU - Riess, Jonathan
AU - Frankel, Paul
AU - Schwartz, Erich
AU - Bennis, Robyn
AU - Hsieh, H. Ben
AU - Liu, Xiaohe
AU - Ly, Janey C.
AU - Zhou, Lisa
AU - Nieva, Jorge J.
AU - Wakelee, Heather A.
AU - Bruce, Richard H.
PY - 2012/8
Y1 - 2012/8
N2 - Purpose: To utilize a novel circulating tumor cell (CTC) technology to quantify ERCC1 expression on CTCs and determine whether ERCC1 expression levels predict efficacy of platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer (NSCLC). Experimental design: ERCC1 expression was measured in 17 metastatic NSCLC patients who received platinum-based therapy and had ≥2 intact CTCs with acceptable ERCC1 expression assay results. ERCC1 levels were determined from average expression on individual CTCs in each sample. Progression-free survival (PFS) was calculated from the date of therapy initiation. Results: PFS decreased with increasing ERCC1 expression (p<0.04, F-test, linear regression). Lack of ERCC1 expression was associated with longer PFS (266 days versus 172 days, log-rank, p<0.02) in a Kaplan-Meier analysis using ERCC expression level of 1 as a cutoff (range 0-30). The difference in survival was statistically significant with a hazard ratio of 4.20 (95% CI 1.25-14.1, p<0.02, log-rank). PFS was also observed to decrease with increased cytokeratin (CK) expression (p<0.01 long-rank (Cox regression) and F-test (linear regression)). The hazard ratio is 4.38 (95% CI 1.76-10.9) for each log-change in CK value until progression was noted on imaging. Conclusion: Low expression of ERCC1 on CTCs correlates with PFS in patients with metastatic NSCLC receiving platinum-based therapy.
AB - Purpose: To utilize a novel circulating tumor cell (CTC) technology to quantify ERCC1 expression on CTCs and determine whether ERCC1 expression levels predict efficacy of platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer (NSCLC). Experimental design: ERCC1 expression was measured in 17 metastatic NSCLC patients who received platinum-based therapy and had ≥2 intact CTCs with acceptable ERCC1 expression assay results. ERCC1 levels were determined from average expression on individual CTCs in each sample. Progression-free survival (PFS) was calculated from the date of therapy initiation. Results: PFS decreased with increasing ERCC1 expression (p<0.04, F-test, linear regression). Lack of ERCC1 expression was associated with longer PFS (266 days versus 172 days, log-rank, p<0.02) in a Kaplan-Meier analysis using ERCC expression level of 1 as a cutoff (range 0-30). The difference in survival was statistically significant with a hazard ratio of 4.20 (95% CI 1.25-14.1, p<0.02, log-rank). PFS was also observed to decrease with increased cytokeratin (CK) expression (p<0.01 long-rank (Cox regression) and F-test (linear regression)). The hazard ratio is 4.38 (95% CI 1.76-10.9) for each log-change in CK value until progression was noted on imaging. Conclusion: Low expression of ERCC1 on CTCs correlates with PFS in patients with metastatic NSCLC receiving platinum-based therapy.
KW - Circulating tumor cells
KW - ERCC1
KW - Non-small-cell lung cancer
KW - Platinum-based chemotherapy
KW - Prognostic diagnostic
UR - http://www.scopus.com/inward/record.url?scp=84863775812&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84863775812&partnerID=8YFLogxK
U2 - 10.1016/j.lungcan.2012.04.005
DO - 10.1016/j.lungcan.2012.04.005
M3 - Article
C2 - 22555222
AN - SCOPUS:84863775812
VL - 77
SP - 421
EP - 426
JO - Lung Cancer
JF - Lung Cancer
SN - 0169-5002
IS - 2
ER -